Identification Of Antigenic Proteins Of Salmonella Enterica Subspecies Enterica Serovar Typhi In Sera Of Patients With Acute Typhoid Fever by Chin, Kai Ling
  
IDENTIFICATION OF ANTIGENIC PROTEINS 
OF Salmonella enterica subspecies enterica serovar 
Typhi IN SERA OF PATIENTS WITH ACUTE 
TYPHOID FEVER 
  
 
 
 
 
CHIN KAI LING 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2016 
  
IDENTIFICATION OF ANTIGENIC PROTEINS 
OF Salmonella enterica subspecies enterica serovar 
Typhi IN SERA OF PATIENTS WITH ACUTE 
TYPHOID FEVER 
 
 
 
by 
 
 
 
CHIN KAI LING 
 
 
 
 
 
Thesis submitted in fulfillment of the requirements 
for the degree of  
Doctor of Philosophy 
 
June 2016 
 ii 
 
ACKNOWLEDGEMENT 
Firstly, thank you God for giving me the strength and patience throughout this whole 
Ph.D journey to complete this thesis. I would like to express my sincere gratitude to 
my supervisor, Prof. Phua Kia Kien and my field supervisor, Prof. Prabha Balaram. 
Without their knowledge, constructive comments, encouragement, and effort in 
research and writing, this task would not have been completed.  
 
My stay at INFORMM was made easy, thanks to all the kind lecturers, helpful 
administration and laboratory staff members, and supportive friends and colleagues. 
Special thanks goes to Prof. Armando Acosta, Prof. Maria Elena Sarmiento, Prof. 
Tan Soo Choon, Dr. Eugene Ong Boon Beng, Dr. Nurul Hasanah, Nur Eliyana 
Redhuan, Goay Yuan Xin, Faizul Rahman, Aziana Ismail, Hemaniswarri Dewi, Amy 
Amilda Anthony, En. Badrul Syam, Basyirah Ghazali, and members of the proteomic 
laboratory, who were involved directly or indirectly in this research. I would also like 
to thank all INFORMM postgraduate students for their support. With their help and 
encouragement from my family members, I have been able to complete this project. 
  
My gratitude also goes to Institute of Postgraduate Studies (IPS), Universiti Sains 
Malaysia for giving me the opportunity to continue my study. Also, thanks to 
MyBrain15 (MyPhD) for providing the financial support throughout my studies, and 
to the Enteric Diseases Research Cluster (Grant no. 1001/PSKBP/8630011) for 
providing funding to support this research. 
 
 
 iii 
 
TABLE OF CONTENTS 
  
ACKNOWLEDGEMENT ii 
TABLE OF CONTENTS iii 
LIST OF TABLES viii 
LIST OF FIGURES x 
LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMNS xvi 
ABSTRAK xviii 
ABSTRACT xx 
CHAPTER 1 INTRODUCTION 1 
1.1 Overview of Typhoid Fever 1 
1.2 Background and History of Typhoid Fever 2 
1.3 Epidemiology of Typhoid Fever 4 
1.3.1 Global disease burden 4 
1.3.2 Typhoid carriers 7 
1.3.3 Multidrug resistant strains of S. Typhi 8 
1.3.4 Typhoid vaccination 10 
1.3.5 Mode of transmission 11 
1.4 Nomenclature of Salmonella 13 
1.5 Laboratory Diagnosis of Typhoid Fever 15 
1.5.1 Culture methods 15 
1.5.2 Serotyping 16 
1.5.3 Slide agglutination test – Widal test 17 
1.5.4 Enzyme immunoassay (EIA) 17 
1.5.5 Rapid diagnostic test kits for typhoid fever 18 
1.5.6 Molecular diagnostic methods 19 
1.5.7 The demerits of currently available diagnostic methods 19 
1.6 Host Immune System 23 
1.6.1 Non-specific immune system 24 
1.6.2 Specific immune system 25 
1.6.3 The immunological homunculus 27 
1.7 Salmonella Proteins as Biomarkers 29 
1.7.1 Fimbriae and flagella antigens 32 
1.7.2 Lipopolysaccharide (LPS) 32 
 iv 
 
1.7.3 Vi antigen 33 
1.7.4 Outer membrane proteins (OMPs) and porins 34 
1.7.5 Salmonella pathogenicity islands (SPIs) 35 
1.7.6 Bacterial cytoplasmic proteins 36 
1.8 Biomarkers Identification Strategy 37 
1.8.1 Biofluids as sources of sequested antigens for typhoid fever 38 
1.9 Methods to Analyse Proteins 40 
1.9.1 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 40 
1.9.2 Two-dimensional polyacrylamide gel electrophoresis (2D-
PAGE) 41 
1.9.3 Western blot (WB) 41 
1.9.4 Mass spectrometry (MS) 42 
1.10 Problem Statement and Rationale of Study 44 
1.11 Objectives of the Study 47 
1.11.1 General objective 47 
1.11.2 Specific objectives 47 
1.12 Overview of Study 48 
CHAPTER 2 MATERIALS AND METHODS 50 
2.1 Serum Samples 50 
2.2 Grouping of Serum Samples 51 
2.3 Pooled Sera as Source of Antigens 52 
2.4 Analysis of Protein Profiles using SDS-PAGE 52 
2.4.1 Preparation of SDS-PAGE gel 53 
2.4.2 Running the SDS-PAGE 56 
2.5 Determination of Protein Load for SDS-PAGE Analysis 57 
2.6 Method 1: Serum Separation using Affinity Chromatography Column 57 
2.7 Method 2: Serum Separation using Membrane Ultrafiltration Column 60 
2.8 Comparison of Protein Profiles of M1-PTFS-PP and M2-PTFS-PP 63 
2.9 Western Blot Analysis 63 
2.10 Identification of Antigenic Proteins in Preparative SDS-PAGE using 
Western Blot (SDS-PAGE-WB) 65 
2.11 Protein Separation using Two-dimensional Polyacrylamide Gel 
Electrophoresis (2D-PAGE) 66 
2.11.1 Sample preparation and rehydration of the IPG strip 66 
2.11.2 First dimension of 2D-PAGE: Isoelectric focusing (IEF) 67 
 v 
 
2.11.3 IPG strip equilibration for reduction and alkylation 67 
2.11.4 Second dimension of 2D-PAGE: Polyacrylamide gel 
electrophoresis (PAGE) 68 
2.12 Identification of Antigenic Proteins in 2D-PAGE using Western Blot 
(2D-PAGE-WB) 70 
2.13 Mass Spectrometry Analysis 74 
2.14 Cloning and Protein Expression of S. Typhi Recombinant Proteins 76 
2.14.1 Primer design for cloning purpose 78 
2.14.2 Preparation of genomic DNA for PCR amplification 80 
2.14.3 PCR amplification of S. Typhi target genes for cloning 
purpose 80 
2.14.4 Detection of amplified PCR products using agarose gel 
electrophoresis 80 
2.14.5 Purification of amplified PCR products 83 
2.14.6 Preparation of cloning vector (plasmid propagation and 
extraction) 83 
2.14.7 Restriction enzyme digestion 87 
2.14.8 Ligation of linearised plasmid with digested PCR products 88 
2.14.9 Preparation of competent E. coli cells 88 
2.14.10 Transformation assay 90 
2.14.11 Recombinant plasmid propagation, extraction and sequencing 91 
2.14.12 Recombinant protein expression 91 
2.15 Preliminary Study on the Antigenicity of the Recombinant Proteins 
using Western Blot 94 
2.16 Purification of Recombinant Proteins 97 
2.16.1 Purification of recombinant proteins under native condition 97 
2.16.2 Purification of recombinant proteins under denaturing 
condition 98 
2.17 Evaluation of the Sensitivities and Specificities of the Recombinant 
Proteins using Indirect ELISA 99 
2.18 Statistical Analysis 100 
CHAPTER 3 RESULTS 103 
3.1 Overview of Serum Preparation 103 
3.2 Protein Load for SDS-PAGE analysis 103 
3.3 Method 1: Serum Separation using Affinity Chromatography Method 106 
3.4 Method 2: Serum Separation using Membrane Ultrafiltration Method 108 
3.5 Comparison of Protein Profiles of M1-PTFS-PP and M2-PTFS-PP 111 
 vi 
 
3.6 Western Blot Analysis 115 
3.7 Identification of Antigenic Proteins in Preparative SDS-PAGE using 
Western Blot (SDS-PAGE-WB) 119 
3.8 Mass Spectrometry Analysis of Antigenic Proteins in SDS-PAGE 
Bands 126 
3.9 Identification of Antigenic Proteins in 2D-PAGE using Western Blot 
(2D-PAGE-WB) 135 
3.9.1 2D-PAGE-WB analysis of antigenic proteins in Method 1 
protein preparations 135 
3.9.2 2D-PAGE-WB analysis of antigenic proteins in Method 2 
protein preparations 146 
3.10 Mass Spectrometry Analysis of Antigenic Proteins in 2D-PAGE 
Spots 155 
3.11 Cloning and Protein Expression of S. Typhi Recombinant Proteins 161 
3.12 Preliminary Study on the Antigenicity of Recombinant Proteins using 
Western Blot 165 
3.13 Purification of Recombinant Proteins 167 
3.14 Evaluation of the Sensitivities and Specificities of the Recombinant 
Proteins using Indirect ELISAs 169 
CHAPTER 4 DISCUSSION 183 
4.1 Pooled Sera as Source of Antigens and Antibodies 183 
4.2 Method 1: Serum Separation using Affinity Chromatography Method 184 
4.3 Method 2: Serum Separation using Membrane Ultrafiltration Method 186 
4.4 Western Blot 189 
4.5 Identification of Antigenic Proteins in Preparative SDS-PAGE using 
Western Blot (SDS-PAGE-WB) 190 
4.6 Identification of Antigenic Proteins in 2D-PAGE using Western Blot 
(2D-PAGE-WB) 192 
4.7 Mass Spectrometry Analysis 194 
4.7.1 Mass spectrometry analysis of S. Typhi proteins 195 
4.7.2 Mass spectrometry analysis of human proteins 199 
4.8 Antigenicity Studies of S. Typhi Recombinant Proteins using Western 
Blot and Indirect ELISAs 202 
CHAPTER 5 CONCLUSION 207 
5.1 Conclusion of the Study 207 
5.2 Limitations and Suggestions for Future Studies 208 
REFERENCES 211 
 vii 
 
APPENDIXES  231 
APPENDIX A: HUMAN ETHICAL APPROVAL  231 
APPENDIX B: CHEMICALS AND MEDIA 233 
APPENDIX C: BUFFERS AND SOLUTIONS 236 
C1 Preparation of Reagents for SDS-PAGE 236 
C2 Preparation of Reagents for Western Blot 237 
C3 Preparation of Reagents for Two-dimensional Polyacrylamide Gel 
Electrophoresis 239 
C4 Preparation of Reagents for Cloning and Protein Expression 239 
C5 Preparation of Reagents for Protein Purification under Native 
Condition 241 
C6 Preparation of Reagents for Protein Purification under Denaturing 
Condition 242 
C7 Preparation of Reagents for Indirect ELISA 243 
APPENDIX D: MASS SPECTROMETRY RESULTS 244 
D1 Antigenic Proteins in SDS-PAGE 244 
D2 Antigenic Proteins in 2D-PAGE 255 
APPENDIX E: DNA SEQUENCING 264 
E1 DNA Sequencing of Blue Copper Oxidase (CueO) 264 
E2 DNA Sequencing of Outer Membrane Protein C (OmpC) 266 
E3 DNA Sequencing of Transaldolase B (TalB) 267 
E4 DNA Sequencing of Cell Invasion Protein A (SipA) 268 
E5 DNA Sequencing of Flagellar Hook-Associated Protein (FlgK) 270 
E6 DNA Sequencing of Hemolysin E (HlyE) 272 
APPENDIX F: STATISTICAL ANALYSIS 273 
F1 One-Way ANOVA Analysis of OD Reading of Anti-rHlyE 
Antibodies 273 
F2 One-Way ANOVA Analysis of OD Reading of Anti-rOmpC 
Antibodies 275 
F3 One-Way ANOVA Analysis of OD Reading of Anti-rCueO 
Antibodies 277 
F4 One-Way ANOVA Analysis of OD Reading of Anti-rFlgK 
Antibodies 279 
APPENDIX G: PUBLICATIONS 281 
  
 viii 
 
LIST OF TABLES 
 Page 
Table 1.1 Current Salmonella nomenclature (Adapted from Lin and Cheng 
2007). 14 
Table 1.2 Sensitivities and specificities of current rapid antibody-based 
detection tests for typhoid fever. 22 
Table 2.1 Solutions for preparation of resolving and stacking gels for 
SDS-PAGE. 54 
Table 2.2 Forward and reverse primers designed for the ORF of the S. 
Typhi target genes. 79 
Table 2.3 DNA sizes of Salmonella Typhi target genes. 82 
Table 2.4 Molecular weight of Salmonella Typhi target proteins. 93 
Table 2.5 Table showing the calculation of sensitivity, specificity, positive 
predictive value (PPV) and negative predictive value (NPV). 102 
Table 3.1 Comparison of 2 serum separation methods used for treatment 
of PTFS and PNHS. 114 
Table 3.2 Human proteins identified from the 12 kDa band using LC-ESI-
MS/MS analysis. 128 
Table 3.3 Human proteins identified from the 15 kDa band using LC-ESI-
MS/MS analysis. 129 
Table 3.4 Human proteins identified from the 18 kDa band using LC-ESI-
MS/MS analysis. 129 
Table 3.5 Human proteins identified from the 25 kDa band using LC-ESI-
MS/MS analysis. 130 
Table 3.6 Human proteins identified from the 50 kDa band using LC-ESI-
MS/MS analysis. 131 
Table 3.7 Salmonella Typhi proteins identified from immunoprecipitin 
bands using LC-ESI-MS/MS analysis. 134 
Table 3.8 Summary of antigen-antibody binding profile using M1-PTFS-
PP and M1-PNHS-PP as sources of antigens. 145 
Table 3.9 Summary of antigen-antibody binding profile using M2-PTFS-
PP and M2-PNHS-PP as sources of antigens. 154 
Table 3.10 Human proteins identified from 2D-PAGE spots using MALDI-
TOF/TOF analysis. 158 
 ix 
 
Table 3.11 Salmonella Typhi proteins identified from spot M8 using LC-
ESI-MS/MS analysis. 160 
Table 3.12 Sensitivity and specificity of rHlyE as biomarker for typhoid 
fever. 174 
Table 3.13 Sensitivity and specificity of rOmpC as biomarker for typhoid 
fever. 177 
Table 3.14 Sensitivity and specificity of rCueO as biomarker for typhoid 
fever. 179 
Table 3.15 Sensitivity and specificity of rFlgK as biomarker for typhoid 
fever. 181 
 
 
 
  
 x 
 
LIST OF FIGURES 
 Page 
Figure 1.1 Global burden of typhoid fever (Adapted from Crump et al. 
2004). 5 
Figure 1.2 Trend of typhoid fever cases in Malaysia from year 1995 till 
2014 (Data from Ministry of Health, Malaysia, 2015). 5 
Figure 1.3 Trend of typhoid fever cases in Kelantan from year 1994 till 
2014 (Data from Kelantan State Public Health Department, 
2015). 6 
Figure 1.4 Structure of Salmonella Typhi (Modified from University of 
British Columbia). 31 
Figure 1.5  Overview of the experimental workflow. 49 
Figure 2.1 Schematic representation of SDS-PAGE gel preparation. 55 
Figure 2.2 Overview of affinity chromatography separation (Method 1) 
according to manufacturer‟s protocol (Bio-Rad, USA). 59 
Figure 2.3 Overview of membrane ultrafiltration (Method 2) according to 
manufacturer‟s protocol (Millipore, USA). 62 
Figure 2.4 Schematic representation of PAGE gel preparation for second 
dimension 2D-PAGE of isoelectric-focused IPG strip. 69 
Figure 2.5 Western blot of PTFS-PP (antigen) with PTFS (antibody), 
visualised using HRP-conjugated rabbit anti-human IgG or IgM 
as secondary antibody. 72 
Figure 2.6 Western blot of PTFS-PP (antigen) with PNHS (antibody), 
visualised using HRP-conjugated rabbit anti-human IgG or IgM 
as secondary antibody. 72 
Figure 2.7 Western blot of PNHS-PP (antigen) with PTFS (antibody), 
visualised using HRP-conjugated rabbit anti-human IgG or IgM 
as secondary antibody. 73 
Figure 2.8 Western blot of PNHS-PP (antigen) with PNHS (antibody), 
visualised using HRP-conjugated rabbit anti-human IgG or IgM 
as secondary antibody. 73 
Figure 2.9 Overview of cloning and expression of S. Typhi recombinant 
proteins. 77 
Figure 2.10 pET28a plasmid multiple-cloning sites (Adapted from NEB, 
UK). 79 
 xi 
 
Figure 2.11 Vector pET28a (Novagen, USA) using SnapGene viewer. 85 
Figure 2.12 Preliminary study of the antigenicity of the S. Typhi 
recombinant proteins using individual typhoid fever, non-
typhoid fever and normal human sera. 96 
Figure 3.1 The effect of protein load on SDS-PAGE protein profiles. 105 
Figure 3.2 SDS-PAGE protein profiles of untreated PTFS and M1-PTFS-
PP by serum depletion using affinity chromatography with 
different incubation times. 107 
Figure 3.3 SDS-PAGE protein profiles of M2-PTFS-PP in different 
diluents. 110 
Figure 3.4 SDS-PAGE protein profiles of M2-PTFS-PP with different 
times of flushing. 110 
Figure 3.5 SDS-PAGE protein profiles of untreated PTFS and PTFS-PP 
prepared using 2 serum separation methods. 113 
Figure 3.6 Determination of duration of protein transfer time from SDS-
PAGE gel to PVDF membrane. 116 
Figure 3.7 Determination of duration of blocking with 5% skimmed milk. 116 
Figure 3.8 Determination of dilution of HRP-conjugated rabbit anti-human 
IgM antibody. 118 
Figure 3.9 Determination of dilution of HRP-conjugated rabbit anti-human 
IgG antibody. 118 
Figure 3.10 Antibody profile of 3 groups of sera against M1-PTFS-PP, 
visualised using HRP-conjugated rabbit anti-human IgG as 
secondary antibody. 121 
Figure 3.11 Antibody profile of 3 groups of sera against M2-PTFS-PP, 
visualised using HRP-conjugated rabbit anti-human IgG 
secondary antibody. 121 
Figure 3.12 Antibody profile of 3 groups of sera against M1-PNHS-PP, 
visualised using HRP-conjugated rabbit anti-human IgG as 
secondary antibody. 122 
Figure 3.13 Antibody profile of 3 groups of sera against M2-PNHS-PP, 
visualised using HRP-conjugated rabbit anti-human IgG as 
secondary antibody. 122 
Figure 3.14 Antibody profile of 3 groups of sera against M1-PTFS-PP, 
visualised using HRP-conjugated rabbit anti-human IgM 
secondary antibody. 124 
 xii 
 
Figure 3.15 Antibody profile of 3 groups of sera against M2-PTFS-PP, 
visualised using HRP-conjugated rabbit anti-human IgM 
secondary antibody. 124 
Figure 3.16 Antibody profile of 3 groups of sera against M1-PNHS-PP, 
visualised using HRP-conjugated rabbit anti-human IgM as 
secondary antibody. 125 
Figure 3.17 Antibody profile of 3 groups of sera against M2-PNHS-PP, 
visualised using HRP-conjugated rabbit anti-human IgM as 
secondary antibody. 125 
Figure 3.18 Mascot search engine result for human proteins identified from 
the 12 kDa band using LC-ESI-MS/MS analysis. 127 
Figure 3.19 Mascot search engine result for Salmonella proteins identified 
from the 12 kDa band using LC-ESI-MS/MS analysis. 133 
Figure 3.20 Antibody profile of PTFS against in vivo antigens from M1-
PTFS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgM as secondary antibody. 137 
Figure 3.21 Antibody profile of PNHS against in vivo antigens from M1-
PTFS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgM as secondary antibody. 137 
Figure 3.22 Antibody profile of PTFS against in vivo antigens from M1-
PNHS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgM as secondary antibody. 138 
Figure 3.23 Antibody profile of PNHS against in vivo antigens from M1-
PNHS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgM as secondary antibody. 138 
Figure 3.24 Antibody profile of PTFS against in vivo antigens from M1-
PTFS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgG as secondary antibody. 139 
Figure 3.25 Antibody profile of PNHS against in vivo antigens from M1-
PTFS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgG as secondary antibody. 139 
Figure 3.26 Antibody profile of PTFS against in vivo antigens from M1-
PNHS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgG as secondary antibody. 140 
Figure 3.27 Antibody profile of PNHS against in vivo antigens from M1-
PNHS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgG as secondary antibody. 140 
 xiii 
 
Figure 3.28 Antibody profile of PTFS against in vivo antigens from M1-
PTFS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgM as secondary antibody. 142 
Figure 3.29 Antibody profile of PNHS against in vivo antigens from M1-
PTFS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgM as secondary antibody. 142 
Figure 3.30 Antibody profile of PTFS against in vivo antigens from M1-
PNHS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgM as secondary antibody. 143 
Figure 3.31 Antibody profile of PNHS against in vivo antigens from M1-
PNHS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgM as secondary antibody. 143 
Figure 3.32 Antibody profile of PTFS against in vivo antigens from M1-
PTFS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgG as secondary antibody. 144 
Figure 3.33 Antibody profile of PNHS against in vivo antigens from M1-
PTFS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgG as secondary antibody. 144 
Figure 3.34 Antibody profile of PTFS against in vivo antigens from M2-
PTFS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgM as secondary antibody. 147 
Figure 3.35 Antibody profile of PNHS against in vivo antigens from M2-
PTFS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgM as secondary antibody. 147 
Figure 3.36 Antibody profile of PTFS against in vivo antigens from M2-
PNHS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgM as secondary antibody. 148 
Figure 3.37 Antibody profile of PNHS against in vivo antigens from M2-
PNHS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgM as secondary antibody. 148 
Figure 3.38 Antibody profile of PTFS against in vivo antigens from M2-
PTFS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgG as secondary antibody. 149 
Figure 3.39 Antibody profile of PNHS against in vivo antigens from M2-
PTFS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgG as secondary antibody. 149 
Figure 3.40 Antibody profile of PTFS against in vivo antigens from M2-
PNHS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgG as secondary antibody. 150 
 xiv 
 
Figure 3.41 Antibody profile of PNHS against in vivo antigens from M2-
PNHS-PP (pH 4-7), and visualised using HRP-conjugated rabbit 
anti-human IgG as secondary antibody. 150 
Figure 3.42 Antibody profile of PTFS against in vivo antigens from M2-
PTFS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgM as secondary antibody. 152 
Figure 3.43 Antibody profile of PNHS against in vivo antigens from M2-
PTFS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgM as secondary antibody. 152 
Figure 3.44 Antibody profile of PTFS against in vivo antigens from M2-
PTFS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgG as secondary antibody. 153 
Figure 3.45 Antibody profile of PNHS against in vivo antigens from M2-
PTFS-PP (pH 7-10), and visualised using HRP-conjugated 
rabbit anti-human IgG as secondary antibody. 153 
Figure 3.46 2D-PAGE protein profiles of M1-PTFS-PP (pH 4-7) showing 
the location of spots (M1-M8) selected for MALDI-TOF/TOF 
analysis. 156 
Figure 3.47 2D-PAGE protein profiles of M2-PTFS-PP (pH 4-7) showing 
the location of spot (M9) selected for MALDI-TOF/TOF 
analysis. 156 
Figure 3.48 2D-PAGE protein profiles of M1-PTFS-PP (pH 7-10) showing 
the location of spots (M10-M16) selected for MALDI-TOF/TOF 
analysis. 157 
Figure 3.49 2D-PAGE protein profiles of M2-PTFS-PP (pH 7-10). No 
antigenic protein was seen in 2D-PAGE-WB. 157 
Figure 3.50 Agarose gel electrophoresis profiles of amplified PCR products 
for 6 target genes. 163 
Figure 3.51 Agarose gel electrophoresis profiles of 6 recombinant plasmids. 163 
Figure 3.52 SDS-PAGE protein profiles of recombinant proteins. 164 
Figure 3.53 Preliminary study of the antigenicity of the 6 recombinant 
proteins using Western blot. 166 
Figure 3.54 SDS-PAGE protein profiles of the sonicated cells to check for 
protein solubility. 168 
Figure 3.55 SDS-PAGE protein profiles of proteins eluted from Ni-NTA 
column. 168 
 xv 
 
Figure 3.56 ELISA mean OD reading + SD (λ450 nm) for IgG class of 
antibodies of 3 groups of sera for each recombinant protein. 170 
Figure 3.57 ELISA mean OD reading + SD (λ450 nm) for IgM class of 
antibodies of 3 groups of sera for each recombinant protein. 170 
Figure 3.58 ELISA mean OD reading + SD (λ450 nm) for IgA class of 
antibodies of 3 groups of sera for each recombinant protein. 171 
Figure 3.59 IgG, IgA and IgM antibody levels and profiles of 4 groups of 
sera against rHlyE protein. 173 
Figure 3.60 IgG, IgA and IgM antibody levels and profiles of 4 groups of 
sera against rOmpC protein. 176 
Figure 3.61 IgG, IgA and IgM antibody levels and profiles of 4 groups of 
sera against rCueO protein. 178 
Figure 3.62 IgG, IgA and IgM antibody levels and profiles of 4 groups of 
sera against rFlgK protein. 180 
 
 
  
 xvi 
 
LIST OF SYMBOLS, ABBREVIATIONS AND ACRONYMNS 
- Negative or minus 
% Percentage 
+ Positive 
< Less than 
> More than 
~ Approximately 
1X 1 time 
2D-PAGE Two-dimensional polyacrylamide gel electrophoresis 
2D-PAGE-WB Two-dimensional polyacrylamide gel electrophoresis-Western 
blot 
bp Base pair 
CMI Cell-mediated immunity 
DNA Deoxyribonucleic acid 
dNTP Deoxynucleoside triphosphate 
E. coli Escherichia coli 
Eff Efficiency 
EIA Enzyme immunoassay 
ELISA Enzyme-linked immunosorbent assay 
ESI Electrospray ionisation 
g Gram 
HAP High abundance protein 
HRP Horseradish peroxidase 
IEF Isoelectric focusing 
IgA Immunoglobulin A 
IgG Immunoglobulin G 
IgM Immunoglobulin M 
IL Interleukin 
INF Interferon 
IPG Immobilised pH gradient 
IS Immune system 
kDa Kilo Dalton 
L Liter 
LA Luria agar 
LAP Low abundance protein 
LB Luria broth 
LC Liquid chromatography 
LPS Lipopolysaccharides 
M Molar 
mA Milliampere 
MALDI Matrix-assisted laser desorption/ionisation 
MDR Multidrug resistant 
 xvii 
 
mg Milligram 
MHC Major histocompatibility complex 
mL Milliliter 
mM Millimolar 
mm Millimeter 
MS Mass spectrometry 
MS/MS Tandem mass spectrometry 
ng Nanogram 
NPV Negative predictive value 
ºC Degree Celsius 
OD Optical density 
OMPs Outer membrane proteins 
PBS Phosphate-buffered saline 
PCR Polymerase chain reaction  
pH Power of hydrogen 
pI Isoelectric points 
PNHS Pooled Normal Human Sera 
PPV Positive predictive value 
PTFS Pooled Typhoid Fever Sera 
PVDF Polyvinyl difluoride 
QTRAP Hybrid triple quadrupole/linear ion trap  
SD Standard deviation 
S. Typhi Salmonella Typhi 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SDS-PAGE-WB Sodium dodecyl sulfate-polyacrylamide gel electrophoresis-
Western blot 
SPIs Salmonella pathogenicity islands 
Th T-helper cells 
™ 
Trademark 
TOF Time-of-flight 
TTSS Type three secretion system 
V Volt 
v/v Volume per volume 
w/v Weight per volume 
xg Relative centrifugal force 
α Alpha 
β Beta 
γ Gamma 
μA Microampere 
μg Microgram 
μL Microliter 
μm Micrometer 
 xviii 
 
PENGENALPASTIAN PROTEIN ANTIGENIK Salmonella enterica subspecies 
enterica serovar Typhi DALAM SERUM PESAKIT DEMAM KEPIALU 
 
ABSTRAK 
Demam kepialu disebabkan oleh sejenis bakteria Gram-negatif, Salmonella 
enterica subspecies enterica serovar Typhi (S. Typhi). Penyakit ini berleluasa di 
seluruh dunia terutamanya di negara-negara yang mundur atau sedang membangun. 
Oleh sebab kekurangan biopenanda yang sensitif dan spesifik di pasaran, diagnosis 
demam kepialu masih kekal sebagai satu masalah kepada pengamal kesihatan. Ini 
mungkin kerana biopenanda tersebut dikenalpasti dalam keadaan in vitro 
menggunakan kultur mikrobiologi. Infeksi adalah satu proses dinamik dan 
penghasilan antigen bergantung kepada cabaran persekitaran yang dihadapi oleh 
bakteria. Dalam kajian ini, serum pesakit demam kepialu digunakan sebagai sumber 
antigen in vivo kerana ia mengandungi produk fisiologi daripada perumah dan 
bakteria yang dihasilkan ketika infeksi. Namun demikian, kewujudan protein 
manusia dalam kuantiti yang banyak (HAPs) di dalam serum pesakit akan 
menghalang pengesanan protein antigenik yang wujud dalam kuantiti yang sedikit 
(LAPs) dan berat molekul rendah, yang mungkin mengandungi biopenanda yang 
berkaitan dengan penyakit tertentu. Serum daripada pesakit demam kepialu (PTFS) 
dan serum daripada manusia normal (PNHS) diproses menggunakan 2 kaedah, iaitu 
1) afiniti kromatografi untuk memisahkan albumin dan immunoglobulin G (IgG) 
daripada serum, dan 2) ultraturasan membran untuk memisahkan protein berat 
molekul lebih daripada 100 kDa daripada serum. Hasilan pemprosesan serum telah 
dianalisa menggunakan 2 kaedah, iaitu 1) SDS-PAGE-Western blot, dan 2) 2D-
PAGE-Western blot. Hasil kajian menunjukkan kaedah pemprosesan serum yang 
 xix 
 
berlainan memberi profil biopenanda yang berlainan. Antigen berkaitan dengan 
demam kepialu yang dijumpai dalam protein PTFS telah dicirikan menggunakan 
analisa mass spectrometri dan 11 protein S. Typhi dikenalpasti menggunakan LC-
ESI-MS/MS. Analisa bioinformatik digunakan untuk memilih protein S. Typhi yang 
berpotensi untuk digunakan sebagai biopenanda diagnosis demam kepialu. 
Berdasarkan markah ramalan keantigenikan yang tinggi, dan peratusan persamaan 
jujukan dengan Escherichia coli (E. coli) yang rendah, 6 protein S. Typhi, iaitu blue 
copper oxidase (CueO), outer membrane protein C (OmpC), transaldolase B (TalB), 
cell invasion protein A (SipA), flagellar hook-associated protein 1 (FlgK), dan 
hemolysin E (HlyE) telah dipilih untuk kajian seterusnya. Protein-protein 
rekombinan (rCueO, rOmpC, rTalB, rSipA, rFlgK, dan rHlyE) telah dihasilkan 
menggunakan teknik pengklonan DNA untuk mendapatkan kuantiti antigen yang 
mencukupi bagi pembangunan Western blot dan ELISA tidak langsung yang 
bertujuan untuk menguji potensi diagnostik mereka. Analisa Western blot 
menggunakan satu panel serum yang terdiri daripada 4 demam kepialu, 2 bukan 
demam kepialu dan 2 manusia normal menunjukkan hanya rCueO, rOmpC, rFlgK, 
dan rHlyE bertindakbalas dengan antibodi hanya daripada subjek demam kepialu, 
dan bukannya daripada subjek bukan demam kepialu dan manusia normal. ELISA 
tidak langsung digunakan untuk menguji satu panel serum yang terdiri daripada 30 
pesakit demam kepialu, 30 pesakit bukan demam kepialu, dan 30 manusia normal. 
Hasil kajian menunjukkan keempat-empat biopenanda ini adalah spesifik untuk 
demam kepialu dengan spesifikasi lebih daripada 90%. Namun demikian, rHlyE 
mempunyai sensitiviti diagnostik yang paling tinggi iaitu 90% berbanding dengan  
rCueO (50%), rOmpC (50%), dan rFlgK (50%). Maka, rHlyE boleh digunakan 
sebagai biopenanda yang tidak ternilai untuk diagnosis demam kepialu.  
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IDENTIFICATION OF ANTIGENIC PROTEINS OF Salmonella enterica 
subspecies enterica serovar Typhi IN SERA OF PATIENTS WITH ACUTE 
TYPHOID FEVER 
 
ABSTRACT 
Typhoid fever is caused by a Gram-negative bacteria, Salmonella enterica 
subspecies enterica serovar Typhi (S. Typhi). It is a worldwide disease infecting 
mostly the under-developed and developing countries. Due to a lack of sensitive and 
specific biomarkers available in the market, diagnosis of typhoid fever remains a 
problem for the clinician. This may be due to the fact that these biomarkers were 
identified using pure microbiological cultures grown in in vitro conditions. Infection 
is a dynamic process and the expression of antigens depend on the environmental 
challenges faced by the bacteria. This study used serum as a source of in vivo 
antigens as it contains physiological signatures from both host and bacterial origin 
that are produced in vivo during infection. However, the presence of high abundance 
proteins (HAPs) in human serum masks the detection of low abundance proteins 
(LAPs) and low molecular weight proteins, which contain candidate protein 
biomarkers relevant to a particular disease state. Pooled Typhoid Fever Sera (PTFS) 
and Pooled Normal Human Sera (PNHS) were subjected to 2 different serum 
separation methods, i.e. 1) affinity chromatography to remove albumin and 
immunoglobulin G (IgG), and 2) membrane ultrafiltration to remove proteins with 
molecular weights greater than 100 kDa. These protein preparations were then 
subjected to 2 protein analysis methods, i.e. 1) SDS-PAGE-Western blot, and 2) 2D-
PAGE-Western blot. The results showed that different separation methods gave 
different biomarker profiles. Typhoid-related antigens found in PTFS were 
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characterised using mass spectrometry analysis and 11 S. Typhi proteins were 
successfully identified using LC-ESI-MS/MS. Bioinformatic analyses were used to 
select S. Typhi proteins as potential biomarkers for diagnosis of typhoid fever. Based 
on high antigenicity prediction scores and low percentage  sequence similarity with 
Escherichia coli (E. coli), 6 S. Typhi proteins, namely, blue copper oxidase (CueO), 
outer membrane protein C (OmpC), transaldolase B (TalB), cell invasion protein A 
(SipA), flagellar hook-associated protein 1 (FlgK), and hemolysin E (HlyE) were 
selected for further studies. Recombinant proteins (rCueO, rOmpC, rTalB, rSipA, 
rFlgK, and rHlyE) were produced using DNA cloning technique to obtain sufficient 
antigens for development of Western blot and indirect ELISAs to evaluate their 
diagnostic potential. Western blot analysis using a panel of test sera consisting of 4 
typhoid fever, 2 non-typhoid fever and 2 normal human subjects showed that only 
antibodies from typhoid fever sera reacted with rCueO, rOmpC, rFlgK, and rHlyE, 
but not from non-typhoid fever and normal human subjects. Indirect ELISAs were 
used to test a panel of sera consisting of 30 typhoid fever, 30 non-typhoid fever, and 
30 normal human subjects. The results showed that all 4 biomarkers were specific for 
diagnosis of typhoid fever with specificity of more than 90%. However, rHlyE had 
the highest diagnostic sensitivity of 90% compared to rCueO (50%), rOmpC (50%), 
and rFlgK (50%). Thus, rHlyE can serve as an invaluable biomarker for the diagnosis 
of typhoid fever. 
 1 
 
CHAPTER 1 
INTRODUCTION 
 
1.1  Overview of Typhoid Fever 
Typhoid fever, also known as enteric fever, is caused by Salmonella enterica 
subspecies enterica serovar Typhi (S. Typhi). It is a facultative anaerobic Gram-
negative bacteria which belongs to the family of Enterobacteriaceae. It is rod-shaped 
in structure, non-spore forming, capsulated, and possesses peritrichous flagella for 
motility. Among the 2,700 serotypes in the Salmonella species, S. Typhi is the most 
host-restricted pathogen infecting humans, and not non-primate vertebrates (Edsall et 
al., 1960; Raffatellu et al., 2005a). This human-restricted pathogen has made studies 
of this bacterium and its pathogenicity very difficult. 
 
The incubation period for typhoid fever ranges from 10 to 12 days depending on the 
infecting dose of the bacilli and the host immune response (Huang and DuPont, 
2005). S. Typhi is a multi-organ pathogen that inhabits the lymphatic tissues of the 
small intestine, liver, spleen and bloodstream of infected humans, which leads to 
complications, such as ileal perforation (Chalya et al., 2012), typhoid 
encephalopathy (Stanley et al., 2008), and hepatobiliary manifestations (Jagadish et 
al., 1994). Untreated typhoid fever cases result in mortality rates ranging from 10 to 
30%, while treated cases result in 99% survival (Crump et al., 2004). 
 
Any person can get typhoid fever, but those who travel, especially to under-
developed and developing countries are at increased risk due to poor sanitary 
systems, food hygiene, and water quality (Steinberg et al., 2004; Muti et al., 2014). 
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This is because the disease is mainly spread through fecal-oral route. The scenario is 
further accentuated by the present in society of 3 to 5% previously infected 
individuals who show no sign of the disease, but at the same time harbor the 
bacterium. These asymptomatic chronic carriers of the bacteria shed viable 
organisms in their urine or stools that can lead to outbreaks of the disease when food, 
prepared by the carriers, are consumed by the rest of the population (Senthilkumar 
and Prabakaran, 2005; Abera et al., 2010). 
 
In spite of the development of diagnostics and treatment for typhoid fever over the 
past 50 years, the disease remains a public health concern of global magnitude today 
(Buckle et al., 2012). This is mainly due to the lack of sensitive and specific 
diagnostic biomarkers available (Keddy et al., 2011), the inefficient identification of 
typhoid carriers (Baker et al., 2010), the emergence of multidrug resistant strains 
(Senthilkumar and Prabakaran, 2005), and the lack of effective vaccines (Basnyat et 
al., 2005). Moreover, its signs and symptoms are similar to that of other febrile 
diseases, such as malaria, dengue fever, leptospirosis and melidiosis, making clinical 
diagnosis of the disease to be difficult (Zhou and Pollard, 2010).  
 
1.2  Background and History of Typhoid Fever 
Typhoid fever has been known for centuries. However, clinically it is 
indistinguishable from and frequently confused with typhus fever due to similar 
clinical features, such as prolonged febrile illness. Thus, the name typhus-like fever 
was given to typhoid fever (Singh, 2001). In 1695, English physician, Thomas Willis 
documented the clinical description and symptoms of the disease. The progression of 
the disease was described by the French physician, Pierre-Fidèle Bretonneau in the 
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year 1819 through his observation of the changes of the lesions on the mucous 
membrane. He also reported that typhoid fever was transmitted by contact with 
infected sources, such as people, food, faeces, and etc. (JAMA, 1968). In 1829, the 
French physician, Pierre Charles Alexandre Louis proposed the name „typhoid 
fever‟, and in 1856, William Budd hypothesised that the disease was spread through 
contaminated water (Moorhead, 2002). The discovery of the bacillus suspected of 
causing typhoid was first described by Carl Joseph Eberth in 1880. His finding was 
later confirmed by pathologist Georg Theodor August Gaffky in 1884 who improved 
the culture method for isolating the bacillus (August and Konert, 1993).  
 
The first documented American carrier, Mary Mallon was identified in the year 
1907. She was a cook in New York, and was closely associated with 47 illnesses and 
3 deaths. The most deadly carrier was Tony Labella who caused 122 infected cases 
and 5 deaths (Emmeluth et al., 2009). Both of these documented cases had no history 
of the carriers, having a previous clinically-detectable typhoid fever. In order to 
prevent the disease, Almroth Edward Wright developed an effective heat inactivated 
whole-cell typhoid vaccine in 1896 (Plotkin, 2011). Antibiotics were also introduced 
in clinical practice in 1948 (Woodward et al., 1950). Together with the vaccination 
strategies, antibiotic treatments, and proper sanitation managements, most developed 
countries showed declining rates of typhoid fever in the 20
th
 century, and some 
developed countries have successfully eradicated the disease. Nevertheless, typhoid 
fever continues to be a disease that affects population in many under-developed and 
developing countries today.  
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1.3  Epidemiology of Typhoid Fever 
1.3.1 Global disease burden 
In 2010, the worldwide incidence of typhoid fever was estimated to be 13.5 million 
but the actual incidence could be higher due to the lack of sensitivity in blood culture 
test for S. Typhi, and thus the adjusted estimation for typhoid fever incidence could 
be as high as 26.9 million with 269,000 deaths as proposed by Buckle et al. (2012). 
Asia was reported to have the highest incidence rate of typhoid fever, especially in 
South-central and South-eastern Asia, including Malaysia, India, Pakistan, and 
Bangladesh with more than 100 cases per 100,000 population in the year 2000 
(Crump et al., 2004) (Figure 1.1). However, according to the data collected by the 
Ministry of Health, Malaysia was classified as a low endemic region for typhoid 
fever with an annual incidence rate of less than 10 cases per 100,000 population from 
year 1995 to 2014 (Figure 1.2). Among all the states in Malaysia, Kelantan has the 
highest incidence rate of typhoid fever and classified as a medium endemic region 
(10-100 per 100,000) (Shah et al., 2012). The annual typhoid incidence estimated in 
year 2001 for Kelantan was 37 per 100,000 (Wan Mansor et al., 2005), which 
declined to 24.4 per 100,000 in 2003, 10 per 100,000 in 2008, 3.29 per 100,000 in 
2009, and 2.8 per 100,000 in year 2010 (Figure 1.3). This was attributed to 
introduction of proper monitoring and surveillance systems by the Kelantan State 
Public Health Department (Wan Mansor et al., 2011). As shown in Figure 1.3, an 
outbreak of typhoid fever occurred in the year 2005 following a major flood in the 
state. It was reported that wells were contaminated with sewage overflow, and rural 
communities which depended on wells for water supply were infected (Shah et al., 
2012).  
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Figure 1.1: Global burden of typhoid fever (Adapted from Crump et al. 2004). 
 
 
Figure 1.2: Trend of typhoid fever cases in Malaysia from year 1995 till 2014 
(Data from Ministry of Health, Malaysia, 2015). 
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Figure 1.3: Trend of typhoid fever cases in Kelantan from year 1994 till 2014 
(Data from Kelantan State Public Health Department, 2015). 
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Typhoid fever affects any age group but it is considered to be a disease mainly of 
children and young adults. Majority of typhoid fever patients in Kelantan were from 
the age group of 5 to 14 years old (Shah et al., 2012; Ja'afar et al., 2013). However, 
in some endemic countries, such as India, Indonesia and Pakistan, the incidence of 
typhoid fever amongst pre-school children, aged 2 to 5 years, were the highest (Sinha 
et al., 1999; Ochiai et al., 2008). Older people appeared to be relatively immune to 
the disease, presumably because of their frequently-reinforced acquired immunity 
through numerous sub-clinical exposures to the typhoid bacilli (Singh et al., 2007). 
 
1.3.2 Typhoid carriers 
Typhoid carriers are asymptomatic persons, diagnosed through bacteria culture 
methods confirming the presence of S. Typhi in their stool or urine even a year after 
the acute typhoid fever episode. Approximately 3 to 5% of acute typhoid fever adults 
become carriers of the disease (Ismail, 2006). The carrier state of typhoid fever was 
observed to be higher in women in the age group 15 to 45 years (Levine et al., 1982; 
Senthilkumar and Prabakaran, 2005). Large-scale investigations for typhoid carriers 
have been carried out particularly among food handlers. These studies demonstrated 
that food handlers harbor S. Typhi asymptomatically at the rate of 3.2% in Accra, 
Ghana (Mensah et al., 2002), 2.3% in Kumasi, Ghana (Feglo et al., 2004), 1.6% in 
Northwest Ethiopia (Abera et al., 2010), and 2% in Malaysia (Pang and Puthucheary, 
1983). Thus, food handlers in these developing countries may be reservoir for the 
bacteria because no animal carrier of the disease has been reported. The percentage 
of typhoid carriers could be much higher due to the lack of sensitivity in culture 
method. The stool culture method is the „gold standard‟ for S. Typhi detection in 
typhoid carriers, and has a low sensitivity of less than 60% (Gopinath et al., 2012). 
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The detection sensitivity for stool culture has not increased considerably in the last 
few decades. Amongst carriers, stool culture is more difficult due to the low numbers 
of viable bacteria present in the stool, and other procedural limitations, such as the 
need for enrichment media, and presence of other bacteria and normal flora. 
 
During an outbreak, the source of the pathogen is usually food handlers with poor 
hygiene and inadequate knowledge about food safety. This is because most food 
handlers working in the kitchen are young workers including children, which means 
the majority are inexperienced or have low educational background. Also, most of 
them do not have medical checkup including stool examination to exclude the 
possibility of carrier status. Thus, health education intervention must be strengthened 
to ensure food safety during processing and storage in the food service industry 
(Abera et al., 2010). Recently, in October 2015, an outbreak of typhoid fever was 
reported in Kuala Lumpur, and the State Public Health Department found illegal 
foreign workers in the local market who were without proper health screening and 
typhoid vaccination. They were also found to have poor personal hygiene, and their 
shelters were illegal construction sites which lack cleanliness and proper water 
supply (Low et al., 2015). This incidence underscores the need to address the socio-
economic problems of the people as they are linked to carriers which are human 
reservoirs for the disease. As a preventive measure, thousands of screening tests were 
conducted among food handlers in the state to identify the typhoid carriers. 
 
1.3.3 Multidrug resistant strains of S. Typhi 
The first multidrug resistant (MDR) strain of S. Typhi emerged in Southeast Asia in 
the late 1980s, and continued to increase and spread throughout the region (Mirza et 
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al., 1996). MDR S. Typhi that are resistant to all first-line antibiotics, such as 
chloramphenicol, ampicillin, and trimethoprim sulphamethoxazole have been 
associated with severe illness, higher rates of complications and deaths, especially in 
children under the age of 2. They were also associated with a higher probability of 
becoming asymptomatic carriers after recovery (Parry et al., 1998). This has led to 
the use of  second-line antibiotics such as fluoroquinolones (ciprofloxacin and 
ofloxacin), and cephalosporins (ceftriaxone) as alternative drugs (Capoor and Nair, 
2010), but emergence of resistance even to this second-line of antibiotics has been 
reported in Vietnam (Parry et al., 1998), Bangladesh (Ahmed et al., 2006), and India 
(Thamizhmani et al., 2012). Currently, there is no standard therapy for third-line 
antibiotics, raising concerns about further spread of the MDR strains to other 
endemic regions. 
 
A recent study by Wong et al. (2015) showed that whole-genome analysis of 1,832 S. 
Typhi isolates from all over the world identified a single dominant MDR lineage, the 
H58 haplotype. The researchers at Sanger Institute found that the ancestral MDR 
strain originated from the Indian Continent and has spread to other parts of the world, 
including Southeast Asia, Western Asia and East Africa, where it has rapidly 
replaced local S. Typhi strains over the last 30 years, and caused high morbidity and 
mortality typhoid in these countries today (Wong et al., 2015). In Malaysia, even 
though the incidence rate of the H58 haplotype is less than 1% of the isolates studied 
(Ja‟afar et al., 2013), it is possible that Malaysia might experience the same 
“epidemic of transmission” as her neighboring countries in the future. 
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1.3.4 Typhoid vaccination 
There are currently 3 licensed typhoid vaccines: 1) heat-phenol inactivated whole 
cell parenteral vaccine, 2) a mutant S. Typhi Ty21a strain used as live attenuated oral 
vaccine, and 3) purified Vi polysaccharide parenteral vaccine. In a 3-year study of 
the cumulative efficacies of these vaccines, 2 doses of whole cell parenteral vaccine 
was found to be more effective than 3 doses of the Ty21a oral vaccine, or 1 dose of 
the Vi parenteral vaccine. However, whole cell vaccine is more frequently associated 
with adverse side effects and are highly reactogenic, causing high fever, abdominal 
pain, vomiting, and diarrhea (Engels et al., 1998). The Ty21a oral vaccine provides 
protection up to 7 years, whereas the whole cell and Vi parenteral vaccine provide 
good protection for 3 years (WHO, 2015). Due to the limitations of these vaccines, 
the Vi capsular polysaccharide vaccine was modified and conjugated with 
recombinant Pseudomonas aeruginosa exoprotein A (rEPA) (Szu et al., 1987), 
diphtheria toxoid, or tetanus toxoid (Ali et al., 2012) as carrier proteins to improve 
the efficacy of the vaccines for typhoid fever (Szu, 2013). 
 
The introduction of typhoid fever vaccines in routine vaccination programs in 
various parts of the world has been highly beneficial in reducing the burden of the 
disease in terms of lost earnings for the individuals and cost of healthcare to the 
government. But, so far, only 2 countries, i.e. China and Vietnam, have incorporated 
typhoid vaccination into their routine immunisation programs, and only in a limited 
fashion. The reason why these efforts have not been more widely accepted lies in 
part to the fact that most developing countries are uncertain of the real burden of 
typhoid fever, due to the lack of rapid diagnostic tools, infrequency of laboratory 
testing, and poor national reporting system. In the developed world, vaccination 
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efforts face obstacles from well-organised anti-vaccination movements which claim 
that in societies where the prevalence of vaccine-preventable diseases are minimal, 
the side effects of vaccines pose a greater health threat than the diseases themselves 
(Bloom, 2011).  
 
The nature of the antigen and the immune response produced are major factors in the 
success of a vaccination program. Current typhoid vaccines induce a predominantly 
humoral immune response which does not appear to eliminate the bacteria 
completely, especially those residing in niche areas in the body where the antibody 
produced has limited effect. Even when some vaccines elicit cell-mediated immune 
response, the memory is short-lived. These form major obstacles in the long term 
control and management of typhoid fever as the bacteria is not completely eliminated 
from the host. It could either be due to defects in the immune response of the 
individuals or the cleverness of the bacteria in evading the immune system of the 
host. Such individuals remain as healthy carriers of the disease and help the bacteria 
spread and establish itself in endemic areas. 
 
1.3.5 Mode of transmission 
S. Typhi is a host-restricted pathogen where humans are the only natural host and 
reservoir of the bacteria (Raffatellu et al., 2005a). It can survive for a long time in 
fresh water and in cold conditions. Thus, untreated water and unhygienically 
prepared food are at significant risk. Shellfish taken from contaminated water, raw 
fruits and vegetables fertilised with sewage, contaminated milk and milk products, 
and foods exposed to flies are normally contaminated with S. Typhi (WHO, 2014). 
Personal hygiene especially among food handlers should also be monitored by the 
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Public Health Department as chronic carriers harbor S. Typhi in their gallbladder and 
continually excrete millions of the pathogenic bacteria in their faeces. 
 
Pathogenesis of acute typhoid fever involves the enterohepatic circuit. Severe and 
prolonged typhoid fever infection is associated with cholecystitis and cholelithiasis. 
The blockage of the cystic duct with gallstones results in jaundice and accumulation 
of bile in the gall-bladder. This further enhances the establishment of chronic 
carriage as S. Typhi develops resistance to bile, and has the ability to form biofilms 
on gallstones. This helps the bacteria to settle in the biliary passages (gall-bladder) 
and becomes its niche habitat. The bacteria that are excreted in the bile and biofilm, 
can transition into planktonic (free swimming) cells, and then reinvade the intestinal 
wall, or are excreted with feces leading to infection of other individuals (Losonsky et 
al., 1987; Senthilkumar and Prabakaran, 2005). 
 
Outbreaks of typhoid fever may occur amongst institutionalised patients as within the 
institutionalised population there is an increased prevalence of chronic diseases that 
decreases host defense mechanisms against Salmonella, such as disorders of gastric 
acidity, intestinal motility, and depressed cell-mediated immunity. The frequent use 
of antimicrobial agents amongst inmates also decreases protective normal flora, and 
thus increase patient susceptibility (Rafii et al., 2008). The highest mortality rates 
were recorded among children and the elderly due to outbreaks in nurseries and 
nursing homes as their immune responses are lower compared to normal healthy 
persons. Outbreaks at gatherings do occur due to inappropriate food handling and 
foods prepared in bulk off-site are likely to be contaminated during transportation. 
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1.4  Nomenclature of Salmonella 
Salmonella was named after the American bacteriologist, D. E. Salmon who first 
isolated Salmonella choleraesuis from porcine intestines in 1884 (Smith, 1894). 
Unlike other bacterial genera, Salmonella organisms are differentiated by serotyping 
analysis. Even today, new serovars are still being discovered each year which 
increase the complexity of this very large bacterial population (Lin and Cheng, 
2007). The latest report published in year 2014 showed that there are over 2,700 
serovars in the genus Salmonella that are found in different hosts and environments 
(Ezzat et al., 2014).  
 
Seven Salmonella subspecies (I, II, IIIa, IIIb, IV, V, VI) were identified based on 
antibody reactions (Le Minor and Popoff, 1987) (Table 1.1). Six of the subspecies 
belonging to the Salmonella enterica species and were classified into groups: I, 
enterica; II, salamae; IIIa, arizonae; IIIb, diarizonae; IV, houtenae; and VI, indica. 
Formerly, S. bongori belonged to subspecies V, but later it was considered as a 
separate species based on differences demonstrated by DNA relatedness studies 
using DNA-DNA hybridisation method in year 1989. In 2005, a new species, 
Salmonella subterranean was recognised (Lin and Cheng 2007). 
 
The classification system based on serovars in subspecies I are designated by a name 
usually indicative of a geographic origin or usual habitat. For the remaining 
subspecies, antigenic formulae including O (somatic) antigens, H (flagellar) antigens 
(phase 1), and H (flagellar) antigens (phase 2, if present) are determined according to 
the Kauffmann-White scheme for serotype naming purposes (Table 1.1). A colon is 
used to separate each antigen (Lin and Cheng, 2007).   
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Table 1.1: Current Salmonella nomenclature (Adapted from Lin and Cheng 
2007). 
  
Taxonomic position (writing format) and nomenclature 
Genus 
(capitalised, 
italic) 
Species (italic) Subspecies (italic) 
Serotypes (or serovars) 
(1
st
 alphabet capitalised, 
not italic) 
Salmonella enterica enterica  
(or subspecies I) 
Typhi (9,12,Vi:d:-) 
salamae  
(or subspecies II) 
9,46:z:z39 
arizonae  
(or subspecies IIIa) 
43:z29:- 
diarizonae  
(or subspecies IIIb) 
6,7:l,v:1,5,7 
houtenae  
(or subspecies IV) 
21:m,t:- 
indica  
(or subspecies VI) 
59:z36:- 
bongori subspecies V 13,22:z39:- 
subterranea   
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For example, based on the established current nomenclature for Salmonella genera, 
Salmonella enterica subspecies enterica serovar Typhi can also be called Salmonella 
Typhi or S. Typhi. According to the Kauffmann-White scheme, S. Typhi can be 
named as Salmonella subspecies I, 9, 12, Vi:d:- as it is categorised under subspecies 
enterica with the presence of O-9 O-antigen, O-12 O-antigen, and virulence Vi 
polysaccharide antigen at the cell wall, with only phase 1 d-H antigen, and no phase 
2 H-antigen. 
 
1.5  Laboratory Diagnosis of Typhoid Fever 
Many diagnostic tests are currently available in the market for typhoid fever. They 
are antigen-, antibody- or DNA-based. Antigen- and DNA-based tests are important 
for early diagnosis, i.e. first week of infection and their sensitivities depend on the 
number of bacteria presents in the circulation. When immune system recognises 
these foreign antigens, it activates B-cells to produce antibodies to kill the invading 
pathogens. Bacterial proteins and DNAs are degraded and fragmented, which may 
results in false negative identification if antigen- and DNA-based tests are used for 
detection. At this stage, antibody-based tests are more suitable for probable 
identification as clones of B-cells are produced, and IgM antibody peaks at 7-10 days 
of infection, followed by IgG antibody at 14-21 days of infection. Since typhoid 
fever has long incubation period (10-12 days) and the disease usually subsides after 2 
months, antibody-based test might provide a greater value in diagnosis of the disease. 
  
1.5.1 Culture methods 
Bacterial culture in blood still remains the „gold standard‟ for detection of typhoid 
fever as it has a specificity of 100% (Keddy et al., 2011). Culture bottles containing 
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culture medium are incubated with 10 mL of patients‟ blood at 37ºC, and are 
checked for a period of 7 days for evidence of bacterial growth through turbidity or 
gas formation. Positive cultures are sub-cultured on agar plates to encourage the 
growth of fastidious microorganism, whereas negative cultures are discarded after 7 
days. In order to identify or isolate S. Typhi colonies grown in the bottle, different 
selective or differential media are used, such as Salmonella-Shigella (SS) agar, 
deoxycholate-citrate (DCA) agar, xylose lysine deoxychoate (XLD) agar, and 
hektoen enteric (HE) agar. The bacterial colonies are differentiated from other 
Enterobacteriaceae by the pattern of growth and by further biochemical tests, such 
as triple sugar iron (TSI) medium, sulfide-indole-motility (SIM) medium, urease, 
citrate, and methyl-red & Vogues-Proskauer (MR-VP) tests (WHO, 2003). The 
results of blood culture are greatly affected by antibiotic treatments prior blood 
collections, and thus bone marrow cultures may provide positive identifications 
(Farooqui et al., 1991). Also, bacteria culturing method could be done using samples 
from stool and urine for detection of the bacterium, S. Typhi. Stool culture may be 
positive in second week and urine culture from the third week of the infection (Abd 
Elseed, 2015). 
 
1.5.2 Serotyping 
Salmonella bacteria look alike under the microscope. However, there are over 2,700 
serotypes of Salmonella that exist all around the world, which can be differentiated 
based on 2 antigenic structures on their cell surface, namely, the lipopolysaccharide 
O-antigen and the flagella H-antigen using the Kauffman-White scheme. Each of the 
O- and H-antigens have a unique code number. There are 46 O-antigens and 119 H-
antigens that have been reported, and the distinct combination of these 2 antigens 
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help scientists to determine each Salmonella serotype (CDC, 2015), and used in 
current Salmonella nomenclature system as describe in Section 1.4. 
 
1.5.3 Slide agglutination test – Widal test 
Serological tests based on antibody detection provide a convenient laboratory 
method for detection of S. Typhi. The Widal test is an old serological assay for 
detecting antibodies to the O-9, O-12, and d-H antigens of S. Typhi based on the 
principal of bacterial cell agglutination (Widal, 1896). Antibody levels are 
considered significant at dilution of greater than or equal to 1:160, but different cut-
off titers have been reported in the literature (Bakr et al., 2011). Serum agglutinins 
rise abruptly during the second week (day 6-8) of infection for the O-antigen, and the 
third
 
week (day 10-12) for H-antigen (Kundu et al., 2006). If the blood is collected 
too early in the disease, false negative results may occur. Thus, testing a paired 
serum sample obtained at intervals of 7 to 10 days to read a four-fold rise in antibody 
level carries greater significance than single test (Sansone et al., 1972). The Widal 
test is widely used in developing countries because of its low cost, suitability for 
large scale screening, simple to perform, and easy to interpret without the need for 
specialised or expensive equipment.  
 
1.5.4 Enzyme immunoassay (EIA) 
Another common assay used in laboratories today is the enzyme immunoassay 
(EIA). The detecting antigen used in typhoid EIA is usually purified extracts of S. 
Typhi cells. The antigen is derived from various subcellular structures of the 
organism, including lipopolysaccharide (Sippel et al., 1987), outer membrane 
proteins (Barrett et al., 1983; Verdugo-Rodriguez et al., 1993a), flagella antigen and 
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somatic antigen (Fadeel et al., 2011), and virulence Vi antigen (Barrett et al., 1983). 
It has been found that EIA-based tests are generally superior than the Widal 
agglutination test in terms of sensitivity and specificity besides being suitable for 
large scale screening (Lim et al., 1998). 
 
1.5.5 Rapid diagnostic test kits for typhoid fever 
Many rapid diagnostic test kits with higher sensitivity than the blood culture method 
have been developed and are available in the market (Keddy et al., 2011). Typhidot
™
 
is a commercial EIA dot-blot test kit which detects host IgM and IgG antibodies 
against a 50 kDa outer membrane protein, reported to be specific for S. Typhi. It 
takes approximately 2 hours using minimum laboratory resources. Detection of IgM 
antibody alone indicates acute typhoid fever in the early phase of infection, while 
presence of both IgG and IgM suggests acute typhoid in the middle phase of 
infection (Ismail, 2000).  
 
TUBEX
™
 (IDL Biotech, Sollentuna, Sweden) is a simple, rapid, one-step test that 
requires 2-10 minutes to perform. It is a semi-quantitative inhibition binding assay 
that detects the presence of IgM antibodies to S. Typhi O-9 lipopolysaccharide 
antigen by assessing the ability of the test serum to inhibit a reaction between 2 
coloured antigen/antibody-coated reagents. It is reported that this antigen contained 
the rare sugar residue (α-D-tyvelose) which is present not only in S. Typhi but also to 
other Salmonella serogroup D bacteria (Lim et al., 1998), and thus can give rise to 
cross-reactivity and false possibility. 
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1.5.6 Molecular diagnostic methods 
Nucleic acid amplification technology (NAAT) is a platform to amplify and detect 
small amount of nucleic acids from as few as 10 microorganisms (Wain and 
Hosoglu, 2008). It is a DNA-based method to identify the presence of foreign 
microorganisms in the body. It requires a sample preparation step to reduce the 
inhibitory substances found in serum/blood, and to increase the concentration of the 
target DNA. Enrichment media, such as tetrathionate broth and selenite F broth, are 
used to assist the growth of Salmonella bacteria from faeces and sewage samples 
because of very large numbers of competing bacteria in these samples, especially 
Escherichia coli (E. coli) (Pedler and Orr, 1990). After enrichment, DNA is extracted 
from the bacteria and tested using polymerase chain reaction (PCR) assay, which 
include primers or oligonucleotides that target the specific nucleic acid sequence of 
the organism. The PCR products are then used in various platforms, including 
multiplex PCR (Pui et al., 2011), loop-mediated isothermal amplification (LAMP) 
(Abdullah et al., 2014), and lateral-flow dipstick assay (Nor Amalina et al., 2014), 
for identification of S. Typhi. 
 
1.5.7 The demerits of currently available diagnostic methods 
Even though many diagnostic methods for typhoid fever are currently available in 
the market for detection of S. Typhi-specific antigens and genes, and detection of 
host immune response (antibodies) toward target antigens, there are many drawbacks 
to these methods. These problems caused delay in the diagnosis of typhoid fever, and 
thus affect the treatment and management of the patients. 
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Bacterial cell culture for S. Typhi is the „gold standard‟ for typhoid fever. However, 
it has low sensitivity due to failure to isolate the microorganism attributed by several 
factors, including patient treatment with antibiotics, variable time of sample 
collection, inappropriate ratio of culture medium to volume of blood used (Das, 
2007), inappropriate use of bacterial enrichment media, and sampling techniques 
(Chua et al., 2015). Bacteremia occurs in the early stage of the disease and positivity 
of blood cultures are as high as 90% for the first week of infection, but reduces 
subsequently with an overall sensitivity of less than 50%, and drops considerably 
with prior antibiotic therapy. Bone marrow culture has sensitivity of 80%, and 
bacteria may be protected from the presence of systemic antibodies and antibiotics, 
but it requires an invasive procedure to obtain the marrow. Stool culture is usually 
not positive in the acute phase of infection, and about 5% remain positive in 
clinically cured or convalescent cases. However, it is important to monitor the 
carriage of S. Typhi after apparent clinical cure to identify typhoid carriers who act 
as reservoirs for the transmission of the disease. Bacteria cell culture methods are 
time consuming as it requires at least 4 to 7 days for laboratory detection depending 
on the size of the bacterial load (Akoh, 1991; Keddy et al., 2011), and require 
multiple equipment and reagents for bacterial identification and differentiation. Thus, 
it is not suitable for large scale screening. These drawbacks call for the development 
of more sensitive, rapid and specific diagnostic tests. 
 
Serotyping helps to discriminate the serotype in the genus Salmonella, and a 
collection of antisera against the O- and H-antigens are required to confirm a single 
serotype. Thus, it is a costly, laborious and low-throughput method. Furthermore, 
maintaining all the regents is cumbersome and quality control is difficult when 
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managing a full array of antisera make from immunising rabbits (McQuiston et al., 
2004). Rather as a diagnostic method, serotyping is more important for 
epidemiological surveillance studies, outbreak detection, and investigations. 
 
To overcome the low-throughput of the culturing method, many rapid antibody-
based detection tests, such as Widal, Typhidot
™
, and TUBEX
™
, were developed. 
However, due to variation of immune response in each individual and cross-
reactivity of the antigens, these current diagnostic tests lack sensitivity and 
specificity (Table 1.2). 
 
Using Widal test, misdiagnosis may occur as the semi-quantitative slide-
agglutination test is unreliable, and display inter-operator variability with poor 
sensitivity, poor specificity, and low positive predictive value (PPV) (Keddy et al., 
2011). This is because the Widal test uses crude cell extract, and the antigens are 
poorly standardised. It also shares many antigenic determinants with other 
Salmonella species, E. coli, dengue virus, and Plasmodium pathogen (WHO, 2003; 
Verma et al., 2014). Hence, false positive results may be more prevalent in endemic 
areas due to past history of exposure to these diseases, as well as immunisation with 
typhoid vaccine. Also, the presence of these cross-reacting antibodies alter the base-
line cut-off antibody titer of the normal population, resulting in false negative results 
(Pang and Puthucheary, 1983). 
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Table 1.2: Sensitivities and specificities of current rapid antibody-based 
detection tests for typhoid fever 
Diagnostic tests Sensitivity 
(%) 
Specificity 
(%) 
Locations References 
Widal (O- and 
H-antigens) 
71.4 68.4 Ethiopia (Andualem et al., 2014) 
43.9 65.0 Kolkata, India (Das et al., 2013) 
72.0 87.0 Amritsar, India (Khanna et al., 2015) 
Widal (O-
antigen) 
80.9 51.8 Kathmandu, 
Nepal 
(Adhikari et al., 2015) 
87.3 6.9 South Africa and 
Tanzania 
(Keddy et al., 2011) 
Widal (H-
antigen) 
72.2 58.3 Kathmandu, 
Nepal 
(Adhikari et al., 2015) 
95.2 13.8 South Africa and 
Tanzania 
(Keddy et al., 2011) 
Typhidot
™
 59.6 80.0 Bangladesh (Islam et al., 2016) 
96.0 89.5 Amritsar, India (Khanna et al., 2015) 
75.0 60.7 South Africa and 
Tanzania 
(Keddy et al., 2011) 
70.0 80.1 Papau New 
Guinea 
(Siba et al., 2012) 
26.7 61.5 Pakistan (Mehmood et al., 2015) 
TUBEX
™
 60.2 89.9 Bangladesh (Islam et al., 2016) 
76.0 96.0 Amritsar, India (Khanna et al., 2015) 
73.0 69.0 South Africa and 
Tanzania 
(Keddy et al., 2011) 
51.1 88.3 Papau New 
Guinea 
(Siba et al., 2012) 
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Rapid diagnosis kits (Typhidot
™
 and TUBEX
™
) are less sensitive than the Widal test 
(Keddy et al., 2011). They also appear to correlate poorly with blood culture results 
in places such as sub-Saharan Africa (Keddy et al., 2011), India (Dutta et al., 2006), 
Vietnam (Olsen et al., 2004), and Egypt (Fadeel et al., 2011). The sensitivity of 
Typhidot
™
 test was reported to be higher at the onset of the first week of illness as 
compared to TUBEX
™
 test (Olsen et al., 2004). This is probably due to the variation 
in the individual‟s immune response, whereby the time-lapsed between the onset of 
symptoms and serum collection can affect the performance of antibody-based tests.   
 
It has been found that EIA- and PCR-based tests are superior to the Widal cell 
agglutination test, but the former are usually tedious and require multiple steps. In 
EIA, enzyme conjugates require refrigeration and electronic optical density (OD) 
readers are expensive, and thus unsuitable for those living in low resource settings 
(Lim et al., 1998). While for PCR, the sample preparation step is time consuming 
and the DNA amplification step requires sophisticated instruments which are 
expensive (Wain and Hosoglu, 2008). 
 
1.6  Host Immune System 
The host immune system (IS) can be divided into 2 functional categories. The Non-
specific or Innate IS, and the Specific or Adaptive IS. The Innate IS is the primary 
immune defense against invading pathogens, while the Adaptive IS is the secondary 
immune defense and also confers protection against re-infection with the same 
pathogen. Both categories have cellular and humoral components which help them to 
carry out their protective functions either by themselves or in concert with each 
other. 
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1.6.1 Non-specific immune system 
The Non-specific immune defense system against microorganisms entering the body 
is also referred to as Innate IS because it is in-born. The elements of the Innate IS 
include physiological barriers, secretory molecules, and cellular components. The 
physio-chemical barriers and the normal flora in the body are effective in preventing 
invading pathogens from entering and colonising the body (Murphy, 2011). 
Salmonella Typhi enters the body via oral route, and thus it must be able to survive 
the low pH gastric acid barrier to reach the small intestine (Giannella et al., 1972). 
Here, it needs to compete with the normal gut flora present in the gastrointestinal 
tract to invade the intestinal mucosa. The resident gut flora do not cause disease 
because their growth is kept under control by the host‟s defense mechanisms and by 
the presence of other microorganisms. However, when the growth of the normal flora 
is suppressed especially during antibiotic treatment, opportunistic agents such as 
Salmonella may be able to colonise the intestine and cause disease (NIH, 2007; Rafii 
et al., 2008).  
 
Once the pathogen enters the body, an acute response of the Innate IS to the infection 
is inflammation. It is stimulated by humoral factors such as complement which could 
increase the vascular permeability, and enhance the recruitment of phagocytic cells 
(macrophages and neutrophiles), dendritic cells, and natural killer cells to the site of 
infection. These would activate a cascade of intracellular events which result in the 
production of a large array of mediator molecules that will trigger Specific IS. 
 
The cell surface of the phagocytic cells contained receptors called Pattern 
Recognition Receptors (PRRs), such as toll-like receptors (TLRs) and nucleotide-
